Last reviewed · How we verify
CG100649
CG100649 is a selective inhibitor of cathepsin S that reduces inflammatory responses by modulating immune cell activation and antigen presentation.
CG100649 is a selective inhibitor of cathepsin S that reduces inflammatory responses by modulating immune cell activation and antigen presentation. Used for Atopic dermatitis, Other autoimmune and inflammatory conditions.
At a glance
| Generic name | CG100649 |
|---|---|
| Also known as | CG100649 2mg, CG100649 4mg |
| Sponsor | CrystalGenomics, Inc. |
| Drug class | Cathepsin S inhibitor |
| Target | Cathepsin S |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cathepsin S is a cysteine protease involved in antigen processing and immune regulation. By inhibiting cathepsin S, CG100649 suppresses pathogenic immune responses and reduces inflammation in autoimmune and inflammatory conditions. This mechanism is particularly relevant in diseases driven by aberrant T-cell and B-cell activation.
Approved indications
- Atopic dermatitis
- Other autoimmune and inflammatory conditions
Common side effects
Key clinical trials
- Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear. (NA)
- Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649 (PHASE1)
- Phase III Study of CG100649 in Osteoarthritis Patients (PHASE3)
- Study of CG100649 Versus Celecoxib in Osteoarthritis Patients (PHASE2)
- Drug-Drug Interaction Study of "CG-651" in Healthy Volunteer (PHASE1)
- Drug-Drug Interaction Study of "CG100650" in Healthy Volunteers (PHASE1)
- Phase I Study on Multiple Oral Dosing of CG100649 (PHASE1)
- Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG100649 CI brief — competitive landscape report
- CG100649 updates RSS · CI watch RSS
- CrystalGenomics, Inc. portfolio CI